Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?701
How could we forget?543
The Troublemaker542
Long-term oxygen therapy in COPD: what is the evidence?460
A new chance to treat rheumatoid arthritis lung fibrosis?406
Postoperative CPAP after major abdominal surgery397
Alone, lonely, and missed358
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress358
Natalie Mazur—creating an affordable vaccine for RSV346
Cystic fibrosis treatment: hope for all?327
Standards for assessing and reporting adverse events300
IL-6 blockade for COVID-19: a global scientific call to arms291
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis284
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 s269
Measles outbreak challenges Trump's public health vision258
Paediatric pneumonia: catalysing research priorities for the next decade254
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial248
Risk and accuracy of outpatient-identified hypoxaemia for death among suspected child pneumonia cases in rural Bangladesh: a multifacility prospective cohort study237
Social and environmental determinants of health inequities in childhood asthma220
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates218
Home-based monitoring in chronic respiratory diseases: in search of Panacea204
How Glasgow's 1957 tuberculosis screening programme could help countries today196
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials195
What does the expanding CFTR modulator programme mean for people with cystic fibrosis?194
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial188
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome186
Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented181
How to survive a pandemic179
Concerns regarding a suggested long COVID paradigm – Authors' reply179
Cystic fibrosis: a call for papers for ECFS 2022177
A novel validated tool to score symptom burden in exercise-induced laryngeal obstruction: can we simplify patient follow-up and research?172
Do chest x-ray-positive, sputum-negative individuals warrant more attention during tuberculosis screening?171
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock166
First-line treatment for advanced NSCLC in older patients and those with poor performance status162
Time to move away from an oxygen-centric model of pulmonary infarction?161
2023 American Thoracic Society International Conference156
Lifetime lung function trajectories and COPD: when the train derails153
Addressing the origins and health effects of small lungs – Authors' reply152
Optimising eligibility criteria for lung cancer screening149
Saving our planet one puff at a time149
The lung is not a balloon: the self-sealing property of the lung147
US FDA delays decision on Juul and other leading e-cigarette brands147
Baricitinib for patients with severe COVID-19—time to change the standard of care?144
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial141
Tuberculosis prevalence: beyond the tip of the iceberg140
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK140
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis135
Azithromycin for the prevention of chronic lung disease of prematurity: not a silver bullet134
COVID-19 hospital admissions: Brazil's first and second waves compared134
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial133
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease – Authors' reply130
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers129
Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, cont129
Major gaps in childhood pneumonia research priorities remain128
RAS inhibition and COVID-19: more questions than answers?127
How repeated influenza vaccination effects might apply to COVID-19 vaccines125
Risk of COVID-19 hospital admission among children with asthma125
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply123
Once-per-day tacrolimus to reduce chronic lung transplant rejection122
Opioids bring peace to patients with IPF cough121
The course of action for effective anti-cytokine treatment in COVID-19120
Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes120
Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples118
A leap forward in assessing host-directed therapies for tuberculosis117
Could a good night's sleep improve COVID-19 vaccine efficacy?117
Moving from collective to distributed epidemiological cancer research115
Easing the stress of chronic cough114
European Respiratory Society International Congress 2021114
Respiratory support before venovenous ECMO for COVID-19: what is the price?113
Inhaled corticosteroids: not just for asthma, but for COVID-19?112
The burden of tuberculosis in Libya112
The elusive goal of COVID-19 vaccine immunity111
European Respiratory Society International Congress 2022111
Rapid maxillary expansion in paediatric obstructive sleep apnoea111
Emily Stone—from lung cancer screening to tobacco control107
US FDA plans improved tobacco regulation106
Hans: finding acceptance and positivity in mindfulness104
Advancement of asthma management in the past decade104
US Senate committee investigates asthma inhaler prices103
FLiRTing with danger as SARS-CoV-2 variants evolve103
Lung transplantation for COVID-19-associated ARDS102
Multiplex bacterial PCR for antibiotic stewardship in pneumonia101
Chronic obstructive pulmonary disease: 10 years of precision-guided success101
COVID-19, smoking, and cancer: a dangerous liaison100
Pulmonary manifestations of chronic HPV infection in patients with recurrent respiratory papillomatosis99
US EPA strengthens PM2·5 air pollution limits99
Changing how we see COPD98
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?96
The persistent mismeasure of spirometry in women96
Treatment of severe COVID-19: a role for JAK and complement inhibitors?96
Discussions on VT4COVID96
Interstitial lung disease: a decade of progress and hope95
Deji Adegunsoye—tackling the mysteries of pulmonary fibrosis95
Fatal dyspnoea at the Palace of Versailles94
0.12217712402344